06/12/2020
喜讯|迈百瑞完成5亿元B轮融资
Congrats|MabPlex Completes $70M USD Series B Financing
继2018年完成4亿元A轮融资后，烟台迈百瑞国际生物医药有限公司（以下简称“迈百瑞”）于近日顺利完成了B轮融资，融资金额超过5亿元人民币。
Following Series A financing of $60 million USD in 2018, MabPlex International, Ltd. (hereinafter referred to as "MabPlex") recently announced the successful completion of Series B financing of more than $70 million US dollars.
本轮融资由德同资本和华金投资领投，阳光保险、奥博资本（OrbiMed）、招商证券投资、信贞添盈基金、吉富创投、华宸财金、源创投资、华耀资本、烟台财金控股、中晟汇银投资、乾道基金、黎公投资等投资机构参与跟投，其中吉富创投、华宸财金、烟台财金控股、中晟汇银投资作为A轮投资机构，本轮继续追加投资。原股东国投创业通过受让部分老股，再次加码投资。
This round of financing was led by DT Capital andHuajin Investment, and nearly 10 investment institutes participate in the follow-up investment, including OrbiMed and some Series A investors. The success of the Series B financing demonstrated investors’ affirmation and confidence to MabPlex performance and potential.
发展至今，迈百瑞以烟台本部领先的技术平台、先进的GMP设施、丰富的CMC管理经验为基础，充分发挥上海、美国的行业前沿优势，成功建立了国内的领先地位，树立了国际口碑。截至发稿前，迈百瑞已参与了国内外近百个新药的研发，帮助客户获得中国、美国、澳大利亚等国家的20余个临床试验批件，已有4家客户利用迈百瑞提供的临床样品在美国开展I/II期临床试验。随着项目合作的不断深入，迈百瑞配备多个主流品牌2000L一次性生物反应器的细胞培养生产线及大规模ADC生产线，也将陆续为客户提供商业化生产服务。
Based on its leading technology platform, advanced GMP facilities and extensive CMC experience, MabPlex has successfully established its leading position in the biologics CDMO industry with good international reputation. As of press time, MabPlex has participated in nearly 100 CDMO projects for clients in China and and abroad, assisted customers obtain more than 20 IND approvals in China, the United States, Australia and other countries. Among them, 4 customers have already used the MabPlex manufactured products for Phase I/II clinical trials in the United States. Equipped with production lines of 2000L disposable mainstream brand bioreactors and with large-scale ADC production lines, MabPlex is able to provide commercial production services for clients.
关于迈百瑞
作为专业的一站式生物医药CDMO服务供应商，烟台迈百瑞国际生物医药有限公司拥有烟台、上海、美国圣地亚哥三个研发及生产中心，可以为全球客户提供单抗、双抗、融合蛋白、ADC等创新生物药、生物类似药的早期开发、工艺开发、临床样品生产、商业化生产、国内外IND/BLA申报等一站式、定制化服务。目前共有9条200-2000L多规模的细胞培养生产线、2条ADC原液生产线及相配套的抗体制剂生产线、ADC制剂生产线。可按照FDA、EMA、NMPA、TGA等要求完成国内外IND/BLA申报。2019年迈百瑞被认定为国家高新技术企业。
About MabPlex
As the leading professional CDMO enterprise, MabPlex has three R&D and production centers in Yantai, Shanghai and San Diego, which can provide global customers with one-stop customized services from early-stage R&D, process development, GMP manufacturing and global IND/BLA filing (FDA,NMPA,EMA,TGA and etc) for antibody drugs, ADC drugs and other protein related drugs.
MabPlex owns facility of 50,000 square meters with a total of 9 mAb DS GMP production lines, 2 ADC DS production lines, 1 mAb formulation production line and 1 ADC formulation production line, which can provide commercial production from 200L to 12000L (6*2000L) scale to help customers greatly accelerate the progress of drug development and marketing.
关于德同资本
德同资本成立于2006年，是一家国内领先的私募股权投资机构，目前管理逾100亿的多只人民币基金，长期聚焦医疗健康、TMT/消费、高端制造领域的不同阶段项目进行投资，是率先与多个地方政府及实力产业集团建立战略合作关系的投资机构之一，近年来屡次获选中国十大投资机构。
About DT Capital
Established in 2006, DT Capital is a leading private equity investment institution in China, focusing on investment in different stages of medical health, TMT/consumption, and high-end manufacturing. It currently manages more than 1.5 billion USD funds, also been selected as one of China's top ten investment institutions in recent years.
关于华金投资
华金投资是中国企业500强、珠海国企华发集团旗下投资平台。华发集团资产规模超过4000亿元，是珠海较大的综合型企业集团和全国知名企业，从2016年起连续四年跻身“中国企业500 强”，2019年位列330名。近年来，华发集团重点围绕先进制造、医疗健康、新一代信息技术等产业领域，通过华金资本、英飞尼迪、珠海科创投等旗下多个投资平台，陆续投资了200多个行业领军企业和高成长性创新企业。其中，华金资本连续两年入选清科“中国私募股权投资机构50强”榜单。
About Huajin Investment
Huajin Investment is an investment platform parented by Huafa Group (state-owned company based in Zhuhai with assets exceeding 60 billion USD), which has been selected as the “Top 50 Chinese Private Equity Institutions” for two consecutive years.
关于奥博资本
奥博资本 (OrbiMed) 创立于1989年，总部位于美国纽约，是全球较大的专注于生物医疗领域的投资公司之一，目前管理约140亿美元的资产，在全球成功投资了450多家企业。
Founded in 1989 and headquartered in New York, USA, OrbiMed is one of the world's largest investment companies focused on the biomedical field. It currently manages approximately US$14 billion in assets and has successfully invested in more than 450 companies worldwide.
